Key result
In patients undergoing primary stenting for AMI, clopidogrel use was associated with higher rates of recurrent ischemia at 30 days compared to ticlopidine.
Why the study?
Does clopidogrel compared to ticlopidine improve clinical outcomes in patients undergoing primary stenting for acute myocardial infarction?
Cohort (n=1,094)
Yes
Does clopidogrel compared to ticlopidine improve clinical outcomes in patients undergoing primary stenting for acute myocardial infarction?
In a prospective observational analysis of patients undergoing primary stenting for AMI, clopidogrel was associated with higher rates of early recurrent ischemia and bleeding compared to ticlopidine.
Answers are grounded in this paper and cite their sources.
Clopidogrel was associated with higher early ischemia risk than ticlopidine; hypothesis-generating and should not yet change practice in AMI stenting.
OBJECTIVE: The aim of this article is to examine whether clopidogrel and ticlopidine treatments produce similar clinical outcomes for patients receiving primary stenting for acute myocardial infarction (AMI). BACKGROUND: Prior studies have yielded conflicting results on the relative safety and efficacy of clopidogrel and ticlopidine after stent implantation, warranting an evaluation in primary stenting for AMI. METHODS: In the multicenter, prospective CADILLAC trial, patients undergoing primary infarct stenting were treated at operator discretion with either ticlopidine (931 patients) or clopidogrel (163 patients) and then followed for 1 year. Baseline clinical and angiographic characteristics were comparable except for baseline TIMI 0/1 flow (72.5% clopidogrel vs. 63.9% ticlopidine, P = 0.04). RESULTS: Patients receiving clopidogrel had more recurrent ischemia in hospital (6.1 vs. 2.8%, P = 0.02) and at 30 days (10.5 vs. 5.8%, P = 0.02), more moderate and severe bleeding at 30 days (7.4 vs. 2.7%, P = 0.002), and similar rates of stent thrombosis out to 1 year (P = 0.11). By multivariable analysis, clopidogrel use was an independent predictor for recurrent ischemia in hospital (P = 0.0002), and at 30 days (P = 0.012); and of moderate and severe bleeding in hospital (P = 0.002), and at 30 days (P = 0.001). CONCLUSIONS: Despite thienopyridines similarities, their efficacy may be different within the first 30 days of primary stenting for AMI. A prospective, randomized trial is required to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Lansky et al. (2008) conducted a cohort in Acute myocardial infarction (AMI) (n=1,094). Clopidogrel vs. Ticlopidine was evaluated on Recurrent ischemia at 30 days (p=0.02). In patients undergoing primary stenting for AMI, clopidogrel use was associated with higher rates of recurrent ischemia at 30 days compared to ticlopidine.
Synapse has enriched 10 related papers. Consider them for comparative context: